J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline - Johnson & Johnson (NYSE:JNJ)

J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline - Johnson & Johnson (NYSE:JNJ)

On Friday, Johnson & Johnson (NYSE:JNJ) said that the Phase 2b AuTonomy proof-of-concept study of posdinemab did not achieve statistical significance in slowing clinical decline in patients with early Alzheimer's disease. The company said the study was a first-of-its-kind precision approach to evaluating targeted intervention in early Alzheimer's disease. Following a scheduled review that determined posdinemab did not achieve statistical signifi…

J&J abandons Alzheimer's antibody in setback for tau

Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.

J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study

Johnson & Johnson’s anti-tau monoclonal antibody failed to slow the progression of Alzheimer’s in patients with early-stage disease, marking the end of one of the company's most promising candidates. The company said in a ...